CD4 and neoplasm: Consistent with its superior antitumor efficacy, a-CTLA4-TGFβRII was more effective in reducing Tregs, elevating tumor-reactive IFN-γ-expressing CD8+ cells and increasing the CD4+ and CD8+ central memory T cells compared with the combination of a-CTLA-4 and a-PD-1 mAbs (Fig. 5d).